• +1-646-491-9876
    • +91-20-67278686

    Search

    Escherichia coli Infections Pipeline Review H1 2017

    Escherichia coli Infections Pipeline Review H1 2017

    • Report Code ID: RW0001799299
    • Category Pharmaceuticals
    • No. of Pages 152
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Escherichia coli Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

    Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 30 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 15 molecules, respectively.

    Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 7
    Publisher Report Coverage 7
    Escherichia coli Infections - Overview 8
    Escherichia coli Infections - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 16
    Products under Development by Universities/Institutes 19
    Escherichia coli Infections - Therapeutics Assessment 21
    Assessment by Target 21
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Escherichia coli Infections - Companies Involved in Therapeutics Development 29
    Abgentis Ltd 29
    Adenium Biotech ApS 29
    AstraZeneca Plc 30
    Atterx Biotherapeutics Inc 30
    AvidBiotics Corp 31
    Cellceutix Corp 31
    ContraFect Corp 32
    Debiopharm International SA 32
    Emergent BioSolutions Inc 33
    F. Hoffmann-La Roche Ltd 33
    GangaGen Inc 34
    Hsiri Therapeutics LLC 34
    ImmunoClin Corp 35
    Immuron Ltd 35
    Johnson & Johnson 36
    Kyorin Pharmaceutical Co Ltd 36
    Melinta Therapeutics Inc 37
    Merck & Co Inc 37
    Microbiotix Inc 38
    Nabriva Therapeutics AG 38
    Navigen Inc 39
    Nosopharm SAS 39
    Novabiotics Ltd 40
    Paratek Pharmaceuticals Inc 40
    Pherecydes Pharma SA 41
    Phico Therapeutics Ltd 41
    Recce Ltd 42
    Sealife PHARMA GMBH 42
    Soligenix Inc 43
    Syntiron LLC 43
    Tetraphase Pharmaceuticals Inc 44
    Escherichia coli Infections - Drug Profiles 45
    A-3APO - Drug Profile 45
    AA-139 - Drug Profile 47
    AM-8722 - Drug Profile 48
    ASN-200 - Drug Profile 49
    AvR2-V10 - Drug Profile 50
    BC-7634 - Drug Profile 52
    BC-9074 - Drug Profile 53
    BC-9529 - Drug Profile 54
    BC-9563 - Drug Profile 55
    BIZ-20131 - Drug Profile 56
    BIZ-20132 - Drug Profile 57
    BIZ-20133 - Drug Profile 58
    CA-824 - Drug Profile 59
    CC-1807 - Drug Profile 60
    CF-301 - Drug Profile 61
    Debio-1454 - Drug Profile 65
    dusquetide - Drug Profile 66
    EBX-004 - Drug Profile 72
    Escherichia coli (whole cell) vaccine - Drug Profile 73
    Escherichia coli vaccine - Drug Profile 74
    Escherichia coli vaccine - Drug Profile 75
    ETEC [strain B7A] vaccine - Drug Profile 76
    ETEC vaccine - Drug Profile 77
    EV-035 - Drug Profile 78
    GN-4474 - Drug Profile 80
    GNeg Snare - Drug Profile 81
    GYR-12 - Drug Profile 82
    HT-07 - Drug Profile 83
    infectious disease vaccine - Drug Profile 84
    interleukin-22 - Drug Profile 85
    JNJ-63871860 - Drug Profile 86
    JSM-11 - Drug Profile 88
    MBX-2319 - Drug Profile 89
    MDN-0057 - Drug Profile 90
    mirandamycin - Drug Profile 92
    NBTI-5463 - Drug Profile 93
    NOSO-95179 - Drug Profile 94
    NP-432 - Drug Profile 95
    omadacycline tosylate - Drug Profile 96
    Onc-72 - Drug Profile 106
    P-100031 - Drug Profile 107
    Peptides for Infectious Diseases - Drug Profile 108
    Polysaccharides for Bacterial Infections - Drug Profile 109
    PP-0121 - Drug Profile 110
    Proteins for Infectious Diseases - Drug Profile 112
    PT-5 - Drug Profile 113
    RECCE-327 - Drug Profile 114
    Recombinant Protein for Escherichia Coli Infections - Drug Profile 116
    RX-05 - Drug Profile 117
    RXP-873 - Drug Profile 118
    SE-1 - Drug Profile 119
    Shigetec - Drug Profile 120
    SLP-0901 - Drug Profile 121
    SLP-0905 - Drug Profile 122
    Small Molecule for Malaria and Bacterial Infections - Drug Profile 123
    Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 124
    Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 125
    Small Molecules for Escherichia coli Infections - Drug Profile 126
    Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 127
    Small Molecules to Inhibit DbpA for Escherichia coli Infections - Drug Profile 128
    Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 129
    SPR-741 - Drug Profile 130
    Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 133
    Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 134
    Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 135
    Synthetic Peptides for Escherichia Coli Infections - Drug Profile 136
    Synthetic Peptides for Infectious Disease - Drug Profile 137
    TN-5 - Drug Profile 138
    TP-6076 - Drug Profile 139
    Escherichia coli Infections - Dormant Projects 140
    Escherichia coli Infections - Discontinued Products 143
    Escherichia coli Infections - Product Development Milestones 144
    Featured News & Press Releases 144
    Appendix 147
    Methodology 147
    Coverage 147
    Secondary Research 147
    Primary Research 147
    Expert Panel Validation 147
    Contact Us 147
    Disclaimer 148

    List of Tables

    Number of Products under Development for Escherichia coli Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Escherichia coli Infections - Pipeline by Abgentis Ltd, H1 2017
    Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1 2017
    Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1 2017
    Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2017
    Escherichia coli Infections - Pipeline by AvidBiotics Corp, H1 2017
    Escherichia coli Infections - Pipeline by Cellceutix Corp, H1 2017
    Escherichia coli Infections - Pipeline by ContraFect Corp, H1 2017
    Escherichia coli Infections - Pipeline by Debiopharm International SA, H1 2017
    Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
    Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Escherichia coli Infections - Pipeline by GangaGen Inc, H1 2017
    Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
    Escherichia coli Infections - Pipeline by ImmunoClin Corp, H1 2017
    Escherichia coli Infections - Pipeline by Immuron Ltd, H1 2017
    Escherichia coli Infections - Pipeline by Johnson & Johnson, H1 2017
    Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
    Escherichia coli Infections - Pipeline by Merck & Co Inc, H1 2017
    Escherichia coli Infections - Pipeline by Microbiotix Inc, H1 2017
    Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H1 2017
    Escherichia coli Infections - Pipeline by Navigen Inc, H1 2017
    Escherichia coli Infections - Pipeline by Nosopharm SAS, H1 2017
    Escherichia coli Infections - Pipeline by Novabiotics Ltd, H1 2017
    Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
    Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H1 2017
    Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
    Escherichia coli Infections - Pipeline by Recce Ltd, H1 2017
    Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
    Escherichia coli Infections - Pipeline by Soligenix Inc, H1 2017
    Escherichia coli Infections - Pipeline by Syntiron LLC, H1 2017
    Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
    Escherichia coli Infections - Dormant Projects, H1 2017
    Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Escherichia coli Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Escherichia coli Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Abgentis Ltd
    Adenium Biotech ApS
    AstraZeneca Plc
    Atterx Biotherapeutics Inc
    AvidBiotics Corp
    Cellceutix Corp
    ContraFect Corp
    Debiopharm International SA
    Emergent BioSolutions Inc
    F. Hoffmann-La Roche Ltd
    GangaGen Inc
    Hsiri Therapeutics LLC
    ImmunoClin Corp
    Immuron Ltd
    Johnson & Johnson
    Kyorin Pharmaceutical Co Ltd
    Melinta Therapeutics Inc
    Merck & Co Inc
    Microbiotix Inc
    Nabriva Therapeutics AG
    Navigen Inc
    Nosopharm SAS
    Novabiotics Ltd
    Paratek Pharmaceuticals Inc
    Pherecydes Pharma SA
    Phico Therapeutics Ltd
    Recce Ltd
    Sealife PHARMA GMBH
    Soligenix Inc
    Syntiron LLC
    Tetraphase Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//escherichia-coli-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//escherichia-coli-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//escherichia-coli-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments